The International Study to Predict Optimized Treatment in Depression (iSPOT-D): Outcomes from the acute phase of antidepressant treatment

Saveanu, Radu V.; Etkin, Amit; Duchemin, Anne‐Marie; Goldstein-Piekarski, Andrea N.; Gyurak, Anett; DeBattista, Charles; Schatzberg, Alan F.; Sood, Satish; Day, Claire V.; Palmer, Donna M.; Rekshan, William; Gordon, Evian; Rush, A. John; Williams, Leanne M.

doi:10.1016/j.jpsychires.2014.12.018

Cited by 130 publications

(136 citation statements)

References 57 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…The other related possibility is that their findings were related to dose; however, the validity of such explanations is not clear. The doses of all three antidepressants in the international Study to Predict Optimized Treatment in Depression (iSPOT) study were low (Escitalopram 12 mg, Sertraline 62 mg, Venlafaxine 83 mg) (56). Evidence does not suggest that Venlafaxine has significant effects on noradrenaline re-uptake at this dose (57, 58).…”

Section: Discussionmentioning

confidence: 99%

A Systematic Review of Cognitive Predictors of Treatment Outcome in Major Depression

2018

View full text Add to dashboard Cite

Background: Research suggests that only 50% of patients with major depression respond to psychotherapy or pharmacological treatment, and relapse is common. Therefore, there is interest in elucidating factors that help predict clinical response. Cognitive impairment is a key feature of depression, which often persists beyond remission; thus, the aim of this systematic review was to determine whether baseline cognitive functioning can predict treatment outcomes in individuals with depression.Method: Studies examining cognitive predictors of treatment response in depression were identified using Pub Med and Web of Science databases. Given the heterogeneity of outcome measures, the variety of treatment protocols, and the differing ways in which data was presented and analyzed, a narrative rather than meta-analytic review technique was used.Results: 39 studies met inclusion criteria. Findings in younger adult samples were inconclusive. There was some evidence for a predictive effect of executive function and to a lesser extent, psychomotor speed, on treatment response. There was no evidence of learning or memory being associated with treatment response. In older-aged samples, the evidence was much more consistent, suggesting that poor executive function predicts poor response to SSRIs.Conclusions: Findings from the present review suggest that certain aspects of cognitive functioning, particularly executive function, may be useful in predicting treatment response in depression. This is certainly the case in elderly samples, with evidence suggesting that poor executive functioning predicts poor response to SSRIs. With further research, baseline cognitive functioning may serve as a factor which helps guide clinical decision making. Moreover, cognitive deficits may become targets for specific pharmacological or psychological treatments, with the hope of improving overall outcome.

show abstract

Section: Discussionmentioning

confidence: 99%

A Systematic Review of Cognitive Predictors of Treatment Outcome in Major Depression

2018

View full text Add to dashboard Cite

show abstract

“…Study management sites oversaw local study recruitment and participation. There were no differences in participant characteristics as a function of recruitment site, adding weight to the point that MDD patients in primary care requiring treatment are not less depressed than those in speciality settings (for details, Saveanu et al, 2015).…”

Section: Participantsmentioning

confidence: 91%

Cognitive and emotional biomarkers of melancholic depression: An iSPOT-D report

Day

Gatt

Etkin

et al. 2015

Journal of Affective Disorders

Self Cite

View full text Add to dashboard Cite

“…There is considerable evidence that the therapeutic activity of antidepressants is not mediated by their direct synaptic effects, on for example monoamine reuptake, but by the brain's adaptive response to sustained increases in monoaminergic neurotransmission produced by these agents, in a manner akin to the emergence of tolerance in the context of chronic use of habit-forming substances (7). Whatever the precise mechanism of action of currently available antidepressants truly is, their less than optimal efficacy has now been well established in largescale clinical trials such as the Sequenced Treatment Alternatives to Relieve Depression Study (8)(9)(10)(11)(12)(13) and the International Study to Predict Optimized Treatment in Depression (14).…”

mentioning

confidence: 99%

Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression

Newport¹,

Carpenter²,

McDonald³

et al. 2015

AJP

501

377

View full text Add to dashboard Cite

The antidepressant efficacy of ketamine, and perhaps D-cycloserine and rapastinel, holds promise for future glutamate-modulating strategies; however, the ineffectiveness of other NMDA antagonists suggests that any forthcoming advances will depend on improving our understanding of ketamine's mechanism of action. The fleeting nature of ketamine's therapeutic benefit, coupled with its potential for abuse and neurotoxicity, suggest that its use in the clinical setting warrants caution.

show abstract

The International Study to Predict Optimized Treatment in Depression (iSPOT-D): Outcomes from the acute phase of antidepressant treatment

Cited by 130 publications

References 57 publications

A Systematic Review of Cognitive Predictors of Treatment Outcome in Major Depression

A Systematic Review of Cognitive Predictors of Treatment Outcome in Major Depression

Cognitive and emotional biomarkers of melancholic depression: An iSPOT-D report

Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression

Contact Info

Product

Resources

About